Company: AZN
Filing Date: 2025-09-29
Form Type: 6-K
Source: 0001104659-25-094039
Chunk: 11

Company: ASTRAZENECA PLC
Filing Date: 2025-09-29
Form: 6-K
Chunk 11
---
 Harmonised Listing Structure and the related termination of the existing ADR Programme is conditional upon the approval of the Resolution by Shareholders at the General Meeting, notice of which is set out in Part VII ( Notice of General Meeting ) of this document. Subject to such approval being obtained, the Harmonised Listing Structure is expected to take effect by 2 February 2026.

Conditional upon the Harmonised Listing Structure, the listings of the various US dollar bonds issued by the Company and AstraZeneca Finance LLC and currently traded on Nasdaq (the

#### “AstraZeneca US Bonds”
) will be terminated, and the listing and trading of the AstraZeneca US Bonds on the NYSE will commence

<div align='center'>9</div>

TABLE OF CONTENTS

**immediately following the Effective Time. Having the AstraZeneca US Bonds and the AstraZeneca Shares listed on the same US exchange will result in AstraZeneca being subject to regulation by only one US exchange. Shareholder approval is not required for the relisting of the AstraZeneca US Bonds.

Shareholders are advised to read the whole of this document and not just rely on the summary information presented in this Part II ( Explanation of the proposals to implement the Harmonised Listing Structure**

#### ).

#### 2.
**Settlement and Dealings in AstraZeneca Shares following the Settlement System Migration**

Holders of AstraZeneca Shares traded on the London Stock Exchange currently have the option to hold interests in AstraZeneca Shares either directly in certificated form with the holder named on the Register of Members or in uncertificated form through CREST. The AstraZeneca Shares traded on Euroclear Sweden are all currently held in uncertificated form through CREST by Euroclear Sweden as custodian on behalf of the relevant Shareholders. AstraZeneca ADSs are currently traded on Nasdaq pursuant to the ADR Programme.

The precise arrangements for holding interests in AstraZeneca Shares immediately following the Effective Time will vary depending on how such interests are held immediately before the Effective Time, as described in this paragraph 2 and in more detail in Part III ( Settlement and Dealings in AstraZeneca Shares following the Settlement System Migration ) of this document.

Notwithstanding these arrangements, Shareholders and (save in respect of fractional entitlements) holders of AstraZeneca ADSs will continue to have the same economic rights as they have today following implementation of the Settlement System Migration and these changes will not result in